Sign Out
No formal drug-drug interaction studies have been performed with Enspryng.
Population pharmacokinetic (PK) analyses did not detect any effect of AZA, corticosteroids or MMF on the clearance of Enspryng.
The potential for treatment with Enspryng to reduce exposure to concomitant medications metabolized by CYP450 isozymes via blockade of IL-6 signalling has been explored using physiologically based pharmacokinetic (PBPK) modelling approaches.
This indicates that suppression of IL-6 signalling by treatment with Enspryng from the low baseline levels seen in the phase III studies will have only a minor impact on exposure of a range of probe CYP450 substrates (≤15% increase in AUC for all substrates of CYPs 1A2, 3A4, 2D6, 2C19). This indicates that the risk of drug interaction is low, however caution should be exercised when Enspryng is administered or discontinued in patients also receiving CYP450 substrates with a narrow therapeutic index.
